{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:08:02Z","timestamp":1789535282047,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV) is a highly prevalent sexually transmitted infection in the world, particularly among young adults shortly after they become sexually active. Beyond its commonality, HPV is a significant public health concern due to its carcinogenic potential. Globally, HPV is responsible for a substantial number of cancer cases annually, including the vast majority of cervical cancers, as well as a notable proportion of other anogenital cancers. To convey the urgent need for comprehensive prevention strategies, this study aimed to assess HPV test positivity and genotype distribution among individuals referred for HPV testing in Tehran, Iran, over a 14-year period (2011\u20132024), providing the foundational data required to guide future national vaccination and screening programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study examined the demographic characteristics of 6418 individuals (5988 women and 430 men) tested for HPV using data and samples collected from patients visiting a Saeed pathology and genetics laboratory between 2011 and 2024. HPV DNA was extracted from genital samples, (cervical\/vaginal specimens for women, and penile\/urethral swabs and urine for men) representative of both female and male individuals in Tehran, and analyzed for the presence of HPV. Genotyping was performed by real-time PCR (Cobas 4800 and Sansure G26) and Reverse Hybridization (INNO-LiPA and HPV Direct Flow Chip) methods for the identification of high-risk (HR) and low-risk (LR) HPV genotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Over the 14-year study period, HPV prevalence was assessed using four diagnostic methods (INNO-LIPA, HybriSpot, COBAS X480, and Sansure Kit), reflecting the evolution of available laboratory assays over time yielding positive detection rates of 55.7%, 61.5%, 17.2%, and 52.1%, respectively. The proportion of positive HPV test results varied across age groups, with the highest prevalence observed in the 20\u201330 year age group. Within the studied cohort, the HPV positivity rate was 40.8% among female patients and 63.3% among the smaller cohort of male patients. The most frequently detected genotypes overall were 6 (12.3%), 16 (7.1%), 52 (3.6%), and 31 (3.3%), in descending order. Notably, 74.4% (517) of patients reported were asymptomic and were referred for routine screening. Among HPV-positive individuals, 69.5% (163) were asymptomatic. Conversely, 23.0% (106) of HPV- negative individuals reported at least one clinical symptom. Positive HPV rates were 56.3% and 24.5% in single and married subjects, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study contributes valuable insights into HPV prevalence and genotype distribution in samples collected over a 14-year period in Tehran. The high prevalence of HPV infection, particularly with high-risk Genotypes coupled with the highest prevalence observed in the 20\u201330 year age group and HPV-16 being common in younger ages, without clinical sign of infection, underscores the necessity for sustained vigilance in monitoring HPV prevalence, early detection through screening, and targeted prevention programs, and comprehensive cervical cancer prevention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-026-03213-2","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:53:26Z","timestamp":1780977206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and genotype distribution of human papillomavirus (HPV) in Tehran, Iran: a retrospective cross sectional study (2011\u20132024)"],"prefix":"10.1186","volume":"23","author":[{"given":"Nader","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaleh Alizadeh","family":"Halili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Sadat","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"3","key":"3213_CR1","doi-asserted-by":"publisher","first-page":"e2537","DOI":"10.1002\/rmv.2537","volume":"34","author":"J Wolf","year":"2024","unstructured":"Wolf J, Kist LF, Pereira SB, Quessada MA, Petek H, Pille A, et al. Human papillomavirus infection: Epidemiology, biology, host interactions, cancer development, prevention, and therapeutics. Rev Med Virol. 2024;34(3):e2537.","journal-title":"Rev Med Virol"},{"key":"3213_CR2","doi-asserted-by":"publisher","first-page":"552028","DOI":"10.3389\/fpubh.2020.552028","volume":"8","author":"AJ Kombe Kombe","year":"2021","unstructured":"Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front public health. 2021;8:552028.","journal-title":"Front public health"},{"issue":"1","key":"3213_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abd.2020.11.003","volume":"96","author":"GM Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es GM, Vieira \u00c9C, Garcia LC, De Carvalho MLR, Guedes ACM, Ara\u00fajo MG. Update on human papilloma virus-part I: epidemiology, pathogenesis, and clinical spectrum. An Bras Dermatol. 2021;96(1):1\u201316.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"3213_CR4","first-page":"322","volume":"5","author":"J Wu","year":"2025","unstructured":"Wu J, Jin Q, Zhang Y, Ji Y, Li J, Liu X, et al. Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022. J Natl Cancer Cent. 2025;5(3):322\u20139.","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"3213_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41579-021-00617-5","volume":"20","author":"AA McBride","year":"2022","unstructured":"McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2022;20(2):95\u2013108.","journal-title":"Nat Rev Microbiol"},{"key":"3213_CR6","doi-asserted-by":"crossref","unstructured":"Tripathi A, Sahu U. An overview of HPV: Causes, symptoms, and clinical manifestations. Immunopathology, Diagnosis and Treatment of HPV Induced Malignancies. 2022:1\u201319.","DOI":"10.1016\/B978-0-323-91797-1.00003-X"},{"key":"3213_CR7","doi-asserted-by":"crossref","unstructured":"Kardani K, Bolhassani A. Types of benign or malignant diseases associated with HPV infections. HPV Infections: Diagnosis, Prevention, and Treatment. Bentham Science; 2018. pp. 30\u201343.","DOI":"10.2174\/116010005"},{"issue":"1","key":"3213_CR8","first-page":"51","volume":"23","author":"G Nalli","year":"2022","unstructured":"Nalli G, Mastrotta P, Garcia MG, Tatti S, Verd\u00fa S. Detection of oral human papillomavirus (HPV) and its clinical importance. J Dent. 2022;23(1):51.","journal-title":"J Dent"},{"key":"3213_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ijgo.70277","volume":"171","author":"N Bhatla","year":"2025","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2025 update. Int J Gynecol Obstet. 2025;171:87\u2013108.","journal-title":"Int J Gynecol Obstet"},{"key":"3213_CR10","doi-asserted-by":"publisher","first-page":"909223","DOI":"10.3389\/fcimb.2022.909223","volume":"12","author":"Y Mo","year":"2022","unstructured":"Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, et al. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Front Cell Infect Microbiol. 2022;12:909223.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"3213_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/vaccines12070746","volume":"12","author":"M Tobaiqy","year":"2024","unstructured":"Tobaiqy M, MacLure K. A systematic review of human papillomavirus vaccination challenges and strategies to enhance uptake. Vaccines. 2024;12(7):746.","journal-title":"Vaccines"},{"issue":"3","key":"3213_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"key":"3213_CR13","doi-asserted-by":"publisher","unstructured":"Han J, Zhang L, Chen Y, Zhang Y, Wang L, Cai R et al. Global HPV vaccination programs and coverage rates: a systematic review. EClinicalMedicine. 2025;84. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103290.","DOI":"10.1016\/j.eclinm.2025.103290"},{"issue":"1","key":"3213_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12889-023-15417-0","volume":"23","author":"G Shafiee","year":"2023","unstructured":"Shafiee G, Mousavian A-h, Sheidaei A, Ebrahimi M, Khatami F, Gohari K, et al. The 15-year national trends of genital cancer incidence among Iranian men and women; 2005\u20132020. BMC Public Health. 2023;23(1):495.","journal-title":"BMC Public Health"},{"issue":"11","key":"3213_CR15","first-page":"2313","volume":"52","author":"N Pirani","year":"2023","unstructured":"Pirani N, Jafari M, Bagherzadeh R, Keikhosravi M, Pirani H. Cervical cancer prevention, its challenges and solutions in Iran and worldwide: a systematic review. Iran J Public Health. 2023;52(11):2313.","journal-title":"Iran J Public Health"},{"issue":"10224","key":"3213_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","volume":"395","author":"M Brisson","year":"2020","unstructured":"Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575\u201390.","journal-title":"Lancet"},{"issue":"1","key":"3213_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12905-025-03841-w","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Fan Z, Wang J, Guan B, Zhou F, Tang Z, et al. HPV vaccination, screening disparities, and the shifting landscape of cervical cancer burden: a global analysis of trends, inequalities, and policy implications. BMC Womens Health. 2025;25(1):285.","journal-title":"BMC Womens Health"},{"issue":"2","key":"3213_CR18","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8(2):e191\u2013203.","journal-title":"Lancet Global Health"},{"key":"3213_CR19","unstructured":"Khodakarami N, Farzaneh F, Yavari P, Khayamzadeh M, Taheripanah R, Akbari ME. The new guideline for cervical cancer screening in low risk Iranian women. 2014."},{"issue":"3","key":"3213_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1128\/JCM.40.3.902-907.2002","volume":"40","author":"F Coutl\u00e9e","year":"2002","unstructured":"Coutl\u00e9e F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol. 2002;40(3):902\u20137.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"3213_CR21","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3390\/ijms19092704","volume":"19","author":"L Xu","year":"2018","unstructured":"Xu L, Padalko E, O\u0161trbenk A, Poljak M, Arbyn M. Clinical evaluation of INNO-LiPA HPV genotyping EXTRA II assay using the VALGENT framework. Int J Mol Sci. 2018;19(9):2704.","journal-title":"Int J Mol Sci"},{"key":"3213_CR22","doi-asserted-by":"crossref","unstructured":"Dutra I, Foroni I, Couto A, Lima M, Bruges-Armas J. Molecular diagnosis of human papillomavirus. Human Papillomavirus and Related Diseases-From Bench to Bedside-Research aspects Rijeka: InTech. 2012:203\u2009\u2013\u200946.","DOI":"10.5772\/30165"},{"issue":"11","key":"3213_CR23","doi-asserted-by":"publisher","first-page":"01626","DOI":"10.1128\/jcm","volume":"58","author":"K van Eer","year":"2020","unstructured":"van Eer K, Leussink S, Severs TT, van Marm-Wattimena N, Woestenberg PJ, Bogaards JA, et al. Evidence for missing positive results for human papilloma virus 45 (HPV-45) and HPV-59 with the SPF10-DEIA-LiPA25 (version 1) platform compared to type-specific real-time quantitative PCR assays and impact on vaccine effectiveness estimates. J Clin Microbiol. 2020;58(11):01626\u201320. https:\/\/doi.org\/10.1128\/jcm.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"3213_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jviromet.2013.04.018","volume":"193","author":"E Herraez-Hernandez","year":"2013","unstructured":"Herraez-Hernandez E, Alvarez-Perez M, Navarro-Bustos G, Esquivias J, Alonso S, Aneiros-Fernandez J, et al. HPV Direct Flow CHIP: A new human papillomavirus genotyping method based on direct PCR from crude-cell extracts. J Virol Methods. 2013;193(1):9\u201317.","journal-title":"J Virol Methods"},{"key":"3213_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1874357920130927004","volume":"7","author":"E Herraez-Hernandez","year":"2013","unstructured":"Herraez-Hernandez E, Preda O, Alonso S, Pardo RS, Olmo A. Detection and genotyping of human papillomavirus DNA in formalin-fixed paraffin-embedded specimens with the HPV Direct Flow CHIP System. open Virol J. 2013;7:91.","journal-title":"open Virol J"},{"issue":"5","key":"3213_CR26","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/JCM.03386-12","volume":"51","author":"A Rao","year":"2013","unstructured":"Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R, et al. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013;51(5):1478\u201384.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"3213_CR27","first-page":"148","volume":"2","author":"J Yin","year":"2022","unstructured":"Yin J, Cheng S, Liu D, Tian Y, Hu F, Zhang Z, et al. Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with the SPF10 LiPA-25 system. J Natl Cancer Cent. 2022;2(3):148\u201354.","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"3213_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","volume":"40","author":"KS Okunade","year":"2020","unstructured":"Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602\u20138.","journal-title":"J Obstet Gynaecol"},{"key":"3213_CR29","unstructured":"Organization WH. Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization; 2020."},{"key":"3213_CR30","doi-asserted-by":"publisher","unstructured":"Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100293.","DOI":"10.1016\/j.eclinm.2020.100293"},{"issue":"1","key":"3213_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s40944-023-00792-8","volume":"22","author":"M Hojjati","year":"2024","unstructured":"Hojjati M, Reshadati M, Rashidi M, Moghadam AG, Salari N, Abdolmaleki A, et al. The prevalence of human papillomavirus in iranian women\u2019s: a comprehensive systematic review and meta-analysis. Indian J Gynecologic Oncol. 2024;22(1):8.","journal-title":"Indian J Gynecologic Oncol"},{"issue":"3","key":"3213_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.30699\/IJP.2019.90356.1861","volume":"14","author":"MM Kesheh","year":"2019","unstructured":"Kesheh MM, Keyvani H. The prevalence of HPV genotypes in Iranian population: an update. Iran J Pathol. 2019;14(3):197.","journal-title":"Iran J Pathol"},{"issue":"1","key":"3213_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13027-022-00421-7","volume":"17","author":"I Rezaee Azhar","year":"2022","unstructured":"Rezaee Azhar I, Yaghoobi M, Mossalaeie MM, Kollaee Darabi A, Nejadeh AH, Jamshidi M, et al. Prevalence of human papilloma virus (HPV) genotypes between outpatients males and females referred to seven laboratories in Tehran, Iran. Infect Agents Cancer. 2022;17(1):7.","journal-title":"Infect Agents Cancer"},{"key":"3213_CR34","unstructured":"McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence of HPV in adults aged 18\u201369: United States, 2011\u20132014. NCHS data brief. 2017;(280):1\u20138."},{"key":"3213_CR35","doi-asserted-by":"publisher","unstructured":"Pourmohsen M, Simbar M, Nahidi F, Fakor F, Majd HA. HPV risk factors and prevention behaviours: a review. J Clin Diagn Res. 2018;12(12):LE01\u2013LE05. https:\/\/doi.org\/10.7860\/JCDR\/2018\/36510.12398.","DOI":"10.7860\/JCDR\/2018\/36510.12398"},{"issue":"1","key":"3213_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12905-025-03668-5","volume":"25","author":"K Ahmadi","year":"2025","unstructured":"Ahmadi K, Armat R, Shahbazi B, Sasani E, Azad A, Gharibi Z, et al. Prevalence and genotype distribution of HPV infection among women in 2021\u20132023 in southern Iran: The rising trend of HPV infection among women. BMC Womens Health. 2025;25(1):126.","journal-title":"BMC Womens Health"},{"issue":"4","key":"3213_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000485898","volume":"60","author":"R Hamkar","year":"2018","unstructured":"Hamkar R, Shoja Z, Ghavami N, Heydari N, Farahmand M, Jalilvand S. Type-specific human papillomavirus prevalence in Iranian women with normal cervical cytology: the impact of current HPV vaccines. Intervirology. 2018;60(4):125\u201330.","journal-title":"Intervirology"},{"issue":"5","key":"3213_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ajog.2025.02.029","volume":"232","author":"KD Lycke","year":"2025","unstructured":"Lycke KD, Steben M, Garland SM, Woo YL, Cruickshank ME, Perkins RB, et al. An updated understanding of the natural history of cervical human papillomavirus infection-clinical implications. Am J Obstet Gynecol. 2025;232(5):453\u201360.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3213_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s43042-025-00744-1","volume":"26","author":"J Ray","year":"2025","unstructured":"Ray J, Baidya J, Paul DP, Majumdar G, Debbarma S, Sarkar A, et al. Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North\u2013East India. Egypt J Med Hum Genet. 2025;26(1):114.","journal-title":"Egypt J Med Hum Genet"},{"issue":"2","key":"3213_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ygyno.2019.05.026","volume":"154","author":"W Li","year":"2019","unstructured":"Li W, Meng Y, Wang Y, Cheng X, Wang C, Xiao S, et al. Association of age and viral factors with high-risk HPV persistence: a retrospective follow-up study. Gynecol Oncol. 2019;154(2):345\u201353.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3213_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12905-025-03765-5","volume":"25","author":"PS Fathi","year":"2025","unstructured":"Fathi PS, Sofian M, Almasi-Hashiani A, Sadat Larijani M, Ashrafian F, Ramezani A. Insufficient knowledge of Human Papillomavirus among reproductive-aged women from Arak, Iran. BMC Womens Health. 2025;25(1):238.","journal-title":"BMC Womens Health"},{"issue":"1","key":"3213_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13027-025-00669-9","volume":"20","author":"A Shakurnia","year":"2025","unstructured":"Shakurnia A, Salehpoor F, Ghafourian M, Nashibi R. Knowledge and attitudes toward HPV, cervical cancer and HPV vaccine among healthcare providers in Ahvaz, Southwest Iran. Infect Agent Cancer. 2025;20(1):44.","journal-title":"Infect Agent Cancer"},{"issue":"1","key":"3213_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.30699\/jogcr.8.1.11","volume":"8","author":"F Behnamfar","year":"2022","unstructured":"Behnamfar F, Ahmadi Solush F, Allameh T. Age and Cervical Histology, the Most Important Factors to Predict Human Papilloma Virus Clearance. J Obstet Gynecol Cancer Res. 2022;8(1):11\u20136.","journal-title":"J Obstet Gynecol Cancer Res"},{"issue":"1","key":"3213_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/joma2010004","volume":"2","author":"S Patra","year":"2025","unstructured":"Patra S, Shand H, Ghosal S, Ghorai S. HPV and male cancer: pathogenesis, prevention and impact. J Oman Med Association. 2025;2(1):4.","journal-title":"J Oman Med Association"},{"issue":"10","key":"3213_CR45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/OLQ.0000000000001053","volume":"46","author":"M El-Zein","year":"2019","unstructured":"El-Zein M, Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, et al. Determinants of acquisition and clearance of human papillomavirus infection in previously unexposed young women. Sex Transm Dis. 2019;46(10):663\u20139.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"3213_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1086\/596050","volume":"199","author":"B Lu","year":"2009","unstructured":"Lu B, Wu Y, Nielson CM, Flores R, Abrahamsen M, Papenfuss M, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis. 2009;199(3):362\u201371.","journal-title":"J Infect Dis"},{"key":"3213_CR47","unstructured":"Luria L, Cardoza-Favarato G. Human Papillomavirus. StatPearls Publishing, Treasure Island (FL); 2026."},{"issue":"3","key":"3213_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1067\/mob.2003.164","volume":"188","author":"C Mao","year":"2003","unstructured":"Mao C, Hughes JP, Kiviat N, Kuypers J, Lee S-K, Adam DE, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol. 2003;188(3):677\u201384.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"3213_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/PDM.0b013e31827f3f7e","volume":"22","author":"K Cuschieri","year":"2013","unstructured":"Cuschieri K, Kavanagh K, Sinka K, Robertson C, Cubie H, Moore C, et al. Effect of HPV assay choice on perceived prevalence in a population-based sample. Diagn Mol Pathol. 2013;22(2):85\u201390.","journal-title":"Diagn Mol Pathol"},{"key":"3213_CR50","doi-asserted-by":"publisher","first-page":"104336","DOI":"10.1016\/j.jcv.2020.104336","volume":"128","author":"DM Ejegod","year":"2020","unstructured":"Ejegod DM, Hansen M, Christiansen IK, Pedersen H, Quint W, Xu L, et al. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework. J Clin Virol. 2020;128:104336.","journal-title":"J Clin Virol"},{"issue":"1","key":"3213_CR51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12978-018-0645-x","volume":"15","author":"X Liang","year":"2018","unstructured":"Liang X, Carroll X, Zhang W, Zhang W, Liu G, Li S, et al. Socioeconomic and lifestyle factors associated with HPV infection in pregnant women: a matched case-control study in Beijing, China. Reproductive Health. 2018;15(1):200.","journal-title":"Reproductive Health"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03213-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:56:09Z","timestamp":1789534569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03213-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3213"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03213-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8904178\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in a private diagnostic laboratory in Tehran, Iran, over a 14-year period. Written informed consent was obtained from all participants at the time of sample collection. The consent form included permission for the use of biological samples and associated clinical and demographic data (including age, sex, marital status, clinical symptoms, and prior infection history where available) for research purposes. All data were anonymized prior to analysis, and no personally identifiable information was included in the study. The study was conducted in accordance with national regulations governing the use of anonymized laboratory data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"214"}}